ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
May 7, 2020 8:30 AM EDTBAUDETTE, Minn., May 7, 2020 /PRNewswire/ --
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million Adjusted non-GAAP diluted earnings per share of $1.04Integrates Amerigen Pharmaceuticals, Ltd. portfolio
Launches five generic products increasing total commercialized product line to 60 product families
Appoints Patrick D. Walsh interim President and CEO
Suspends guidance for 2020
ANI Pharmaceuticals, Inc.... More
